VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Wang-Gillam Discusses the Mechanism of Action of MM-398

Andrea Wang-Gillam, MD, PhD
Published: Monday, Aug 04, 2014

Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the mechanism of action of MM-398, a novel encapsulation of irinotecan in a long-circulating nanoliposome.

Wang-Gillam says the agent consists of approximately 80,000 irinotecan molecules packed into a stable, liposomal-based nanopartical. This special delivery system allows the drug to stay in the circulation longer and results in a much higher AUC — 70-times higher AUC than conventional irinotecan.

Another feature of MM-398, Wang-Gillam says, is that it allows higher uptake of the drug at the tumor site. When patients who received MM-398 had their tumor biopsied, a 5-times higher active metabolite SM38 was seen compared to what they find in the patients’ blood at baseline.

These two key features make this delivery system much more attractive than conventional irinotecan, Wang-Gillam says.
Andrea Wang-Gillam, MD, PhD, assistant professor, Department of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, discusses the mechanism of action of MM-398, a novel encapsulation of irinotecan in a long-circulating nanoliposome.

Wang-Gillam says the agent consists of approximately 80,000 irinotecan molecules packed into a stable, liposomal-based nanopartical. This special delivery system allows the drug to stay in the circulation longer and results in a much higher AUC — 70-times higher AUC than conventional irinotecan.

Another feature of MM-398, Wang-Gillam says, is that it allows higher uptake of the drug at the tumor site. When patients who received MM-398 had their tumor biopsied, a 5-times higher active metabolite SM38 was seen compared to what they find in the patients’ blood at baseline.

These two key features make this delivery system much more attractive than conventional irinotecan, Wang-Gillam says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x